Blood Test May Guide Breast Cancer Treatment in Older Women | UPMC Hillman Cancer Center

For women aged 70 and over diagnosed with estrogen receptor-positive breast cancer, navigating treatment decisions can be particularly complex. A new study from UPMC Hillman Cancer Center and the University of Pittsburgh School of Medicine suggests a blood test may offer a valuable tool for personalizing treatment plans, specifically when considering endocrine therapy – hormone-blocking treatment – as an alternative to surgery and radiation. The findings, published in Clinical Cancer Research, offer a potential path toward more tailored care for a population where the “right size” of treatment isn’t always clear.

Understanding Estrogen Receptor-Positive Breast Cancer and Treatment Choices

Breast cancer isn’t a single disease; it’s a collection of diseases categorized by how the cancer cells behave and what fuels their growth. Estrogen receptor-positive (ER+) breast cancer means the cancer cells grow in response to the hormone estrogen. This type is the most common, accounting for about 80% of all breast cancers. Standard treatment often involves surgery to remove the tumor, followed by radiation and endocrine therapy to block estrogen’s effects. However, for older women with ER+ breast cancer, particularly those with other health conditions, the potential benefits of aggressive treatment must be carefully weighed against the risks.

Endocrine therapy, such as tamoxifen or aromatase inhibitors, works by either blocking estrogen from reaching cancer cells or by reducing the amount of estrogen the body produces. It’s a less invasive option than surgery and radiation, but its effectiveness can vary. Currently, clinicians often rely on clinical judgment and factors like tumor size and grade to determine if endocrine therapy alone is appropriate. This is where the new blood test could prove beneficial.

How the Blood Test Works and What It Measures

The study focused on identifying biomarkers – measurable substances in the blood – that could predict how well endocrine therapy would work. Researchers analyzed blood samples from a cohort of women aged 70 and older with ER+ breast cancer who were considering endocrine therapy alone. They identified a specific set of biomarkers that, when combined, appeared to correlate with treatment response. While the specific biomarkers haven’t been publicly detailed beyond the study publication, the principle is that these markers reflect the biological activity of the cancer and its sensitivity to hormone-blocking drugs.

The researchers emphasize that this test isn’t intended for all women with breast cancer. It’s designed for a carefully selected group: those over 70, diagnosed with ER+ breast cancer, and contemplating endocrine therapy as their primary treatment, foregoing surgery and radiation. This specificity is crucial, as the test’s accuracy hasn’t been established in other populations.

Study Details and Limitations

The study, conducted by researchers at the UPMC Hillman Cancer Center – a National Cancer Institute-designated Comprehensive Cancer Center – involved a retrospective analysis of existing patient data. UPMC Hillman Cancer Center is recognized for its research in cancer prevention, early detection, and novel therapeutic discovery. The researchers analyzed samples and clinical data from women who had already begun endocrine therapy, looking for correlations between biomarker levels and treatment outcomes.

It’s important to note the limitations inherent in retrospective studies. Because the data was collected after treatment had started, it’s difficult to definitively prove that the biomarkers caused the observed treatment responses. Correlation does not equal causation. There’s a possibility that other factors, not measured in the study, influenced the outcomes. The study population was limited to women in western Pennsylvania, which may limit the generalizability of the findings to other regions or ethnic groups. The researchers acknowledge the need for larger, prospective studies – studies that follow patients forward in time – to validate these findings and determine the test’s true clinical utility.

What This Means for Patients and Clinicians

The potential benefit of this blood test lies in its ability to provide clinicians with more information to guide treatment decisions. Currently, choosing endocrine therapy alone involves a degree of uncertainty. This test could help identify women who are most likely to benefit from this approach, potentially avoiding unnecessary surgery and radiation. Conversely, it could also identify women who are unlikely to respond to endocrine therapy, prompting a discussion about alternative treatment options.

However, it’s crucial to understand that this test is not a definitive answer. It’s a tool to be used in conjunction with clinical judgment and patient preferences. A positive test result doesn’t guarantee success, and a negative result doesn’t necessarily mean endocrine therapy won’t work. The test provides additional data, but the final decision rests with the patient and their healthcare team.

The Role of Comprehensive Cancer Centers in Research

The UPMC Hillman Cancer Center’s involvement in this research highlights the importance of NCI-designated Comprehensive Cancer Centers. These centers, like UPMC Hillman, are recognized for their scientific leadership, resources, and the breadth of their cancer research programs. UPMC Hillman Cancer Center offers access to clinical trials and a range of cancer treatments. They play a critical role in translating laboratory discoveries into new and improved treatments for patients. The center’s collaborative approach, bringing together basic researchers and clinicians, is essential for accelerating the pace of cancer research.

What Comes Next: Validation and Implementation

The next steps involve validating these findings in larger, more diverse populations. Researchers plan to conduct prospective clinical trials to confirm the test’s accuracy and determine its impact on patient outcomes. These trials will also help refine the test and identify the optimal way to use it in clinical practice. If the results are confirmed, the blood test could become a standard part of the treatment decision-making process for older women with ER+ breast cancer. The process of integrating a new test into clinical guidelines typically involves review by professional organizations, such as the American Society of Clinical Oncology (ASCO), and updates to national treatment guidelines.

For patients and caregivers, the most important step is to continue having open and honest conversations with their healthcare team about treatment options and potential benefits and risks. Staying informed about the latest research and advancements in cancer care is also crucial. You can find more information about breast cancer and treatment options from reputable sources like the National Cancer Institute and the Breastcancer.org.